|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-3-4
|
|
pubmed:abstractText |
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% to 60% of glioblastoma multiforme tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases. We sought to determine whether glioblastoma multiforme expression of either overexpressed wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall patient survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1462-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15746047-Adolescent,
pubmed-meshheading:15746047-Adult,
pubmed-meshheading:15746047-Aged,
pubmed-meshheading:15746047-Aged, 80 and over,
pubmed-meshheading:15746047-Cohort Studies,
pubmed-meshheading:15746047-Female,
pubmed-meshheading:15746047-Glioblastoma,
pubmed-meshheading:15746047-Humans,
pubmed-meshheading:15746047-Immunohistochemistry,
pubmed-meshheading:15746047-Male,
pubmed-meshheading:15746047-Middle Aged,
pubmed-meshheading:15746047-Prognosis,
pubmed-meshheading:15746047-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15746047-Retrospective Studies,
pubmed-meshheading:15746047-Survival Analysis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
|
|
pubmed:affiliation |
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA. aheimber@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
